Apyx Medical Corporation Common Stock (APYX)
Stock · NASDAQ · Health Care
$2.56as of 10/16/2026
Price chart
Active signals
APYX Signal Track Record
How signals performed across all stocks →What APYX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 47 | -0.8% | 47% | September 28, 2026 |
| Bollinger Band Breakdown | 22 | +0.2% | 50% | September 24, 2026 |
| Bollinger Band Breakout | 21 | +7.1% | 57% | June 5, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -17.3% | 25% | July 23, 2026 |
| Any 20-session window (baseline) | -1.6% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About APYX
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue du…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 205
- Website
- apyxmedical.com/
Fundamentals
- 1-day range
- $2.54$2.65
- Market cap
- $174.35M
- P/E (trailing)
- —
- P/E (forward)
- -10.13
- EPS (trailing)
- $-0.20
- Dividend yield
- —
- Beta
- 1.53
- Avg. volume
- 133.0K
How Apyx Medical Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 10, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Apyx Medical Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- APYXApyx Medical Corporation Common Stock$2.55▼ 0.39%Market cap $174.35MP/E —$2.32$5.08
- KRMDKORU Medical Systems Inc. Common Stock (DE)$3▼ 0.99%Market cap $163.52MP/E —$2.86$6.61
- CVRXCVRx Inc. Common Stock$1.3▼ 6.47%Market cap $157.62MP/E —$1.28$11.3
- STIMNeuronetics Inc. Common Stock$1.88▼ 3.33%Market cap $156.57MP/E —$0.8$3.44
- LUCDLucid Diagnostics Inc. Common Stock$0.478▼ 8.08%Market cap $193.54MP/E —$0.5$1.63
- RCELAvita Medical Inc. Common Stock$13.04▼ 2.76%Market cap $146.19MP/E —$3.22$13.73
- EMBCEmbecta Corp. Common Stock$6.27▼ 2.79%Market cap $207.65MP/E 4.00$2.77$14.91
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| APYX Apyx Medical Corporation Common Stock | $174.35M | — | $2.55 | ▼ 0.39% | $2.32$5.08 |
| KRMD KORU Medical Systems Inc. Common Stock (DE) | $163.52M | — | $3 | ▼ 0.99% | $2.86$6.61 |
| CVRX CVRx Inc. Common Stock | $157.62M | — | $1.3 | ▼ 6.47% | $1.28$11.3 |
| STIM Neuronetics Inc. Common Stock | $156.57M | — | $1.88 | ▼ 3.33% | $0.8$3.44 |
| LUCD Lucid Diagnostics Inc. Common Stock | $193.54M | — | $0.478 | ▼ 8.08% | $0.5$1.63 |
| RCEL Avita Medical Inc. Common Stock | $146.19M | — | $13.04 | ▼ 2.76% | $3.22$13.73 |
| EMBC Embecta Corp. Common Stock | $207.65M | 4.00 | $6.27 | ▼ 2.79% | $2.77$14.91 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin QualityYahoo · 9/29/2026
- InMode: Hope Is Not An Effective Investment Strategy, But Neither Is DespairSeekingAlpha · 9/25/2026
- Cold Plasma Market Forecasts Growth from $3.32B (2025) to $8.45B by 2032, Profiling Nordson Corporation, Apyx Medical, Plasmatreat & Enercon IndustriesYahoo · 9/24/2026
- Cold Plasma Market Forecasts Growth from $167.8M (2025) to $495.9M by 2033, Profiling Apyx Medical, Neoplas Med, Adtec Healthcare & 5 Other Key PlayersYahoo · 9/15/2026
Insider Activity
Insider Actions →- Lawrence Waldman · June 30, 2026 · Tax Withholding5.0K @ $4.49
- Lawrence Waldman · June 30, 2026 · Option Exercise12.0K @ $1.88
- Shawn David Roman · June 11, 2026 · Grant88.0K
- Levine Wendy Lauren · June 11, 2026 · Grant50.0K
- Minnie Baylor-Henry · June 11, 2026 · Grant50.0K
- Goodwin Charles D. II · June 11, 2026 · Grant213.9K
- Stavros G. Vizirgianakis · June 11, 2026 · Grant450.0K
- Lawrence Waldman · June 11, 2026 · Grant50.0K
- Moshe Citronowicz · June 11, 2026 · Grant63.4K
- Matthew C. Hill · June 11, 2026 · Grant132.1K
Institutional Ownership
March 31, 2026
- Total shares held
- 20.40M
- Total value held
- $74.91M
- Institutional holders
- 64
- Unknown3.44M
- Unknown2.79M
- Unknown2.61M
- Unknown1.56M
- Unknown1.10M
- Unknown1.04M
- Unknown901.4K
- Unknown649.1K
- Unknown615.0K
- Unknown598.3K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Apyx Medical featured in cold plasma market growth report
Apyx Medical was named as a key player in a new report projecting the cold plasma market to grow from $3.32 billion in 2025 to $8.45 billion by 2032. This industry-level forecast highlights the long-term potential of the sector in which Apyx operates. The company's stock is currently trading below its average analyst target price, reflecting ongoing market uncertainty despite these broader industry trends.
Apyx Medical featured in cold plasma market growth report. Apyx Medical was named as a key player in a new report projecting the cold plasma market to grow from $3.32 billion in 2025 to $8.45 billion by 2032. This industry-level forecast highlights the long-term potential of the sector in which Apyx operates. The company's stock is currently trading below its average analyst target price, reflecting ongoing market uncertainty despite these broader industry trends.